Acute Alcoholic Hepatitis
9
1
1
3
Key Insights
Highlights
Success Rate
43% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
44.4%
4 terminated out of 9 trials
42.9%
-43.6% vs benchmark
22%
2 trials in Phase 3/4
167%
5 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
Integrative Epidemiology of Prognosis in Patients With Acute Alcoholic Hepatitis at AP-HP
Digoxin In Treatment of Alcohol Associated Hepatitis
MRG-001 in Patients With Alcoholic Hepatitis
Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis
Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF